Effective April 28, 2021, Bexsero® (meningococcal group B vaccine) was added to the ADAP formulary. This vaccine is administered as a two-dose regimen, given at least one month apart, and will provide protection against invasive disease caused by serogroup B. Bexsero® was approved by the United States Food and Drug Administration in 2015 for use in those aged 10-25 years.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the addition of Bexsero®, available at: (https://cdph.magellanrx.com/member/documents).

If you have any questions regarding the addition of this medication to the ADAP formulary, please contact James Vo, ADAP Specialist, at (916) 449-5965.

Thank you,